Acetohydroxamic acid
From Wikipedia, the free encyclopedia
 |
|
 |
|
| Clinical data | |
|---|---|
| AHFS/Drugs.com | Consumer Drug Information |
| ATC code | |
| Identifiers | |
|
|
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| ECHA InfoCard | 100.008.104 |
| Chemical and physical data | |
| Formula | C2H5NO2 |
| Molar mass | 75.0666 g/mol |
| 3D model (Jmol) | |
|
|
|
|
| (verify) | |
Acetohydroxamic acid (also known as AHA or Lithostat) is a drug that is a potent and irreversible inhibitor of bacterial and plant urease usually used for urinary tract infections. The molecule is similar to urea but is not hydrolyzable by the urease enzyme.[1]
Orphan drug[edit]
In 1983 the US Food and Drug Administration approved acetohydroxamic acid (AHA) as an orphan drug for "prevention of so-called struvite stones" under the newly enacted Orphan Drug Act of 1983.[2] AHA cannot be patented because it is a standard chemical compound.[2]
References[edit]
- ^ W. Fishbein; P. Carbone (June 1965). "Urease catalysis. ii. Inhibition of the enzyme by hydroxyurea, hydroxylamine, and acetohydroxamic acid". J Biol Chem. 240: 2407–14.
- ^ a b Marwick, Charles (1983). "New drugs selectively inhibit kidney stone formation". The Journal of the American Medical Association. 240 (3): 321–322. doi:10.1001/jama.1983.03340030003001.
See also[edit]
 |
This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it. |
